Prostate cancer is a common malignant tumor in the male reproductive system, and metastatic hormone-sensitive prostate cancer (mHSPC) has long been a key focus and challenge in clinical treatment due to its rapid progression and high treatment difficulty. Rezvilutamide tablets, as a new type of androgen receptor inhibitor independently developed in China, bring new treatment hope to such...